Susceptibility testing of Candida glabrata clinical strains to echinocandins using SensititreTM YeastOneTM system | CMAC

Susceptibility testing of Candida glabrata clinical strains to echinocandins using SensititreTM YeastOneTM system

Clinical Microbiology and Antimicrobial Chemotherapy. 2018; 20(1):49-54

​ Veselov A.V., Vasilyeva N.V., Bogomolova T.S., Raush E.R., Kutsevalova O.Yu., Nizhegorodceva I.A., Petrova L.V., Shmidt N.V., Moskvitina E.N., Sukhorukova M.V., Ivanchik N.V., Kozlov R.S.
10.36488/cmac.2018.1.49-54
Сandida glabrata candidiasis echinocandins resistance
Section
Antimicrobial Resistance
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2018; 20(1):49-54

Objective.

To determine susceptibility of C. glabrata isolates to anidulafungin, caspofungin and micafungin using the SensititreTM YeastOneTM system.

Materials and Methods.

C. glabrata isolates were taken prospectively from clinical specimens or from strains collections in the participating sites. Susceptibility determination was performed using SensititreTM YeastOneTM (YO10 panel) according to the manufacturer’s guidance, and results were interpreted with M27-A3 CLSI guidelines. Susceptibility of C. glabrata to fluconazole was also determined in order to assess possible correlations of echinocandins and fluconazole minimal inhibitory concentrations (MICs) in resistant strains.

Results.

A total of 59 C. glabrata strains were tested. The strains were isolated mostly from peripheral blood (44%). Among clinically significant medical conditions/risk factors and co-morbidities, central venous catheter, solid tumors, and abdominal surgery were identified in 20 (33.9%), 19 (32.2%), and 14 (23.7%) patients, respectively. Most MIC values of echinocandins were 0.015 and 0.03 mg/L. Caspofungin has slightly higher MIC values than those of anidulafungin and micafungin. No isolates were resistant to any of the echinocandins. The only 2 patients were receiving echinocandin therapy at the time of taking biosamples (with no reported information about treatment efficacy); those strains were also susceptible to all echinocandins. All C. glabrata strains were susceptible dose-dependent to fluconazole with MIC values between 2 and 32 mg/L.

Conclusions.

All of the echinocandins have a high and comparable in vitro activity against C. glabrata, including strains which are susceptible dose-depended to fluconazole. More prospective studies are needed to investigate the long-term trends in susceptibility profiles of pathogens causing candidiasis, especially C. glabrata.

Alexander V. Veselov

Institute of Antimicrobial Chemotherapy, Smolensk, Russia

Vasilyeva N.V.

Kashkin Research Institute of Medical Mycology, North-Western State Medical University named after I.I. Mechnikov, Saint-Petersburg, Russia
North-Western State Medical University named after I.I. Mechnikov, Saint-Petersburg, Russia

Bogomolova T.S.

Kashkin Research Institute of Medical Mycology, North-Western State Medical University named after I.I. Mechnikov, Saint-Petersburg, Russia
North-Western State Medical University named after I.I. Mechnikov, Saint-Petersburg, Russia

Raush E.R.

North-Western State Medical University named after I.I. Mechnikov, Saint-Petersburg, Russia

Kutsevalova O.Yu.

Rostov Research Institute of Oncology, Rostov-on-Don, Russia

Nizhegorodceva I.A.

Regional Clinical Hospital №2, Krasnodar, Russia

Petrova L.V.

Regional Clinical Hospital №2, Krasnodar, Russia

Shmidt N.V.

Branch Clinical Hospital at Volgograd-1 station JSC Russian Railways, Volgograd, Russia

Ekaterina N. Moskvitina

Siberian Federal Research Clinical Centre of the Federal Medical Biological Agency, Seversk, Russia

Marina V. Sukhorukova

Institute of Antimicrobial Chemotherapy, Smolensk, Russia

Nataly V. Ivanchik

Institute of Antimicrobial Chemotherapy, Smolensk, Russia

Roman S. Kozlov

Institute of Antimicrobial Chemotherapy, Smolensk, Russia

  • 1. McCarty T., Pappas P. Invasive Candidiasis. Infect Dis Clin North Am. 2016;30(1):103-124.
  • 2. Ostrosky-Zeichner L., Al-Obaidi M. Invasive Fungal Infections in the Intensive Care Unit. Infect Dis Clin North Am. 2017;31(3): 475-487.
  • 3. Fortún J., Gioia F. Invasive candidiasis in the neutropenic patient. Rev Esp Quimioter. 2017;30(Suppl 1):22-25.
  • 4. Gallagher J., MacDougall C., Ashley E., Perfect J. Recent advances in antifungal pharmacotherapy for invasive fungal infections. Expert Rev Anti Infect Ther. 2004;2(2):253-268.
  • 5. Sanguinetti M., Posteraro B., Lass-Flörl C. Antifungal drug resistance among Candida species: mechanisms and clinical impact. Mycoses. 2015;58(Suppl. 2):2-13.
  • 6. Diekema D., Arbefeville S., Boyken L., et al. The changing epidemiology of healthcare-associated candidemia over three decades. Diagn Microbiol Infect Dis. 2012;73:45-48.
  • 7. Cleveland A., Harrison L., Farley M., et al. Declining incidence of candidemia and the shifting epidemiology of Candida resistance in two US metropolitan areas, 2008-2013: results from population-based surveillance. PLoS One. 2015;10:e0120452.
  • 8. Pfaller M., Andes D., Diekema D., et al. Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004-2008. PLoS One. 2014;9(7):e101510.
  • 9. Vasilyeva N., Raush E., Rudneva M., et al. Etiology of invasive candidosis agents in Russia: a multicenter epidemiological survey. Front Med. 2018;12(1):84-91.
  • 10. Patil A., Majumdar S. Echinocandins in antifungal pharmacotherapy. J Pharm Pharmacol. 2017;69(12):1635-1660.
  • 11. Pappas P., Kauffman C., Andes D., et al. Clinical practice guidelines for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1-e50.
  • 12. Cornely O., Bassetti M., Calandra T., et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012;18(Suppl. 7):19-37.
  • 13. Ullmann A., Akova M., Herbrecht R., et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect. 2012;18(Suppl. 7):53-67.
  • 14. Diagnosis and treatment of mycoses in intensive care units: Russian recommendations. Klimko N.N., Ed. 2nd Edition. M.: Farmtek, 2015. 96 p. Russian.
  • 15. Park S., Kelly R., Kahn J., et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother. 2005;49:3264-3273.
  • 16. Perlin D. Resistance to echinocandin-class antifungal drugs. Drug Resist Updat. 2007;10:121-130.
  • 17. Available from: www.clsi.org.
  • 18. Available from: www.eucast.org.
  • 19. Pfaller M., Chaturvedi V., Diekema D., et al. Clinical evaluation of the Sensititre YeastOne colorimetric antifungal panel for antifungal susceptibility testing of the echinocandins anidulafungin, caspofungin, and micafungin. J Clin Microbiol. 2008;46(7):2155-2159.
  • 20. Espinel-Ingroff A., Alvarez-Fernandez M., Cantón E., et al. Multicenter Study of Epidemiological Cutoff Values and Detection of Resistance in Candida spp. to Anidulafungin, Caspofungin, and Micafungin Using the Sensititre YeastOne Colorimetric Method. Antimicrob Agents Chemother. 2015;59(11):6725-6732.
  • 21. Aigner M., Erbeznik T., Gschwentner M., Lass-Flörl C. Etest and Sensititre YeastOne Susceptibility Testing of Echinocandins against Candida Species from a Single Center in Austria. Antimicrob Agents Chemother. 2017;61:e00512-17.
  • 22. Posteraro B., Spanu T., Fiori B., et al. Antifungal susceptibility profiles of bloodstream yeast isolates by Sensititre YeastOne over nine years at a large Italian teaching hospital. Antimicrob Agents Chemother. 2015;59(7):3944-3955.
  • 23. Kulko A.B. In vitro anidulafungin activity against yeasts – system and disseminated mycosis pathogens. Onkogematologija. 2015;10:53-57. Russian.
  • 24. Fedorova N.I., Kulko A.B. Study of susceptibility of Candida parapsilosis clinical strains isolated in different hospitals to antifungal drugs. The Journal “Bulletin of Pirogov National Medical and Surgical Center”. 2015;10(4):69-71. Russian.
  • 25. Eschenauer G., Nguyen M., Shoham S., et al. Real-world experience with echinocandin MICs against Candida species in a multicenter study of hospitals that routinely perform susceptibility testing of bloodstream isolates. Antimicrob Agents Chemother. 2014;58:1897-1906.
  • 26. Pfaller M., Boyken L., Hollis R., et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol. 2008;46(1):150-156.
  • 27. Pfaller M., Castanheira M., Messer S., Moet G., Jones R. Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009). Diagn Microbiol Infect Dis. 2011;69(1):45-50.
  • 28. Pfaller M., Rhomberg P., Messer S., Jones R., Castanheira M. Isavuconazole, micafungin, and 8 comparator antifungal agents’ susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values. Diagn Microbiol Infect Dis. 2015;82(4):303-313.
  • 29. Xiao M., Fan X., Chen S., et al. Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillance. J Antimicrob Chemother. 2015;70(3):802810.
  • 30. Pham C., Iqbal N., Bolden C., et al. Role of FKS Mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance. Antimicrob Agents Chemother. 2014;58(8):4690-4696.
  • 31. Castanheira M., Woosley L., Messer S., et al. Frequency of fks mutations among Candida glabrata isolates from a 10-year global collection of bloodstream infection isolates. Antimicrob Agents Chemother. 2014;58:577-580.
  • 32. Klimko N., Vasilyeva N., Chernenkaya T., et al. Invasive candidiasis in intensive care units: results of prospective multicenter study in Russia. Proceedings of the 25th ECCMID, Copenhagen, Denmark, April 25-28, 2015. Abstr. EV0945.
  • 33. Klyasova G., Malchikova A., Maschan M., et al. In vitro activity of echinocandins and azoles against Candida spp. Isolated from hematological (Hem) and non-hematological (non-Hem) patients in 11 centers of Russia. Mycoses. 2017;60(Suppl. 2):65.
  • 34. Shields R., Nguyen M., Press E., et al. The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata. Antimicrob Agents Chemother. 2012;56:4862-4869.
  • 35. Beyda N., John J., Kilic A., et al. FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia. Clin Infect Dis. 2014;59(6):819-825.
  • 36. Shields R., Nguyen M., Press E., et al. Rate of FKS mutations among consecutive Candida isolates causing bloodstream infection. Antimicrob Agents Chemother. 2015;59(12):7465-7470.
  • 37. Dudiuk C., Gamarra S., Leonardeli F., et al. Set of classical PCRs for detection of mutations in Candida glabrata FKS genes linked with echinocandin resistance. J Clin Microbiol. 2014;52:2609-2614.
  • 38. Pham C., Bolden C., Kuykendall R., Lockhart S. Development of a Luminex-based multiplex assay for detection of mutations conferring resistance to Echinocandins in Candida glabrata. J Clin Microbiol. 2014;52(3):790-795.
  • 39. Zhao Y., Nagasaki Y., Kordalewska M., et al. Rapid Detection of FKSAssociated Echinocandin Resistance in Candida glabrata. Antimicrob Agents Chemother. 2016;60(11):6573-6577.
  • 40. Hamdy R., Zaoutis T., Seo S. Antifungal stewardship considerations for adults and pediatrics. Virulence. 2017;8(6):658-672.
  • 41. Micallef C., Ashiru-Oredope D., Hansraj S., et al. An investigation of antifungal stewardship programmes in England. J Med Microbiol. 2017;66(11):1581-1589.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared